{"name": "glycerol phenylbutyrate", "category": "drug", "content": "Glycerol phenylbutyrate, sold under the brand name  Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body. It is an FDA-approved prescription drug in the US. It was developed by Hyperion Therapeutics based on the existing medication sodium phenylbutyrate, and received approval in February 2013.   == Society and culture ==   === Economics === Hyperion has been criticized for setting a high price for the drug. The price was set at US$250,000\u2013290,000. In 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive Buphenyl ($113.6 million in sales).   == References =="}